Coherus BioSciences, Inc. ("Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a ...

4 The liver cancer treatment pattern has changed in recent years with the emergence of immunotherapy combinations and will continue to evolve as more treatment options become available for these ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today ...

Merry Christmas from the Hales, who are spending the holidays in the European country of Turkey (Turkiye), where Alan has been undergoing treatment for his cancer since the first week of October.

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors bought 14,331 put options on the stock. This ...

It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

Liver cancer rates have more than tripled in the U.S. since 1980 and continue to rise. More than 41,000 people will be ...

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental ...

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental study, pharmacological inhibition of an enzyme that plays a central role in ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 ...